BIOTECH firm Emergex has raised more than US$11 million in a Series A funding round to develop synthetic vaccines for infectious diseases, it said on Thursday.Founded in 2016, Emergex focuses on developing vaccines to prevent diseases such as Zika, dengue fever, Ebola and the pandemic flu.
According to the company, its vaccines are unlike traditional vaccines which use live viruses. Instead, Emergex uses synthetic non-biological components that"programme immune cells to destroy pathogen-producing cells", it said. In addition, chairman of Vickers Venture Partners Finian Tan will also join Emergex's board as a non-executive director.
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: BusinessTimes - 🏆 15. / 51 Read more »